Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Prepaid Assets (2016 - 2025)

Ligand Pharmaceuticals' Prepaid Assets history spans 16 years, with the latest figure at $5.8 million for Q4 2025.

  • For Q4 2025, Prepaid Assets fell 34.31% year-over-year to $5.8 million; the TTM value through Dec 2025 reached $5.8 million, down 34.31%, while the annual FY2025 figure was $5.8 million, 34.31% down from the prior year.
  • Prepaid Assets for Q4 2025 was $5.8 million at Ligand Pharmaceuticals, down from $7.0 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $19.7 million in Q3 2024 and bottomed at $1.1 million in Q4 2022.
  • The 5-year median for Prepaid Assets is $5.4 million (2021), against an average of $6.1 million.
  • The largest annual shift saw Prepaid Assets plummeted 80.49% in 2023 before it skyrocketed 841.39% in 2024.
  • A 5-year view of Prepaid Assets shows it stood at $3.6 million in 2021, then crashed by 68.3% to $1.1 million in 2022, then rose by 4.42% to $1.2 million in 2023, then surged by 645.01% to $8.8 million in 2024, then crashed by 34.31% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Prepaid Assets are $5.8 million (Q4 2025), $7.0 million (Q3 2025), and $4.8 million (Q2 2025).